These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22274144

  • 1. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM, Vecera KF, Barnes KN, Reski JW, Forinash AB.
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab for neovascular ocular diseases.
    Lynch SS, Cheng CM.
    Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998
    [Abstract] [Full Text] [Related]

  • 3. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.
    Retina; 2006 Apr; 26(5):495-511. PubMed ID: 16770255
    [Abstract] [Full Text] [Related]

  • 4. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW.
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS, Custis P, Howes J, Hsu JW.
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM, Noureddine BN, Bashshur ZF.
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [Abstract] [Full Text] [Related]

  • 7. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV.
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [Abstract] [Full Text] [Related]

  • 8. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M, Sharma S.
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U.
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [Abstract] [Full Text] [Related]

  • 10. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P, Mariotti C, Arapi I, Bambini E, Giovannini A.
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [Abstract] [Full Text] [Related]

  • 11. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [Abstract] [Full Text] [Related]

  • 12. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB, Sjølie AK, Møller F.
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.
    Ophthalmologica; 2009 Nov; 223(6):370-5. PubMed ID: 19590252
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U.
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [Abstract] [Full Text] [Related]

  • 16. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
    Vedula SS, Krzystolik MG.
    Cochrane Database Syst Rev; 2008 Apr 16; (2):CD005139. PubMed ID: 18425911
    [Abstract] [Full Text] [Related]

  • 17. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug 16; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration associated with poor initial visual acuity.
    Galbinur T, Averbukh E, Banin E, Hemo I, Chowers I.
    Br J Ophthalmol; 2009 Oct 16; 93(10):1351-2. PubMed ID: 19520693
    [Abstract] [Full Text] [Related]

  • 19. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug 16; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Aug 16; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.